Cited 49 times in
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.